Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keymed BiosciencesFRA:64Z +1.81%44 Days Payable is 128.95 as of Dec. 2025, which is 42% below its 10-year median of 221.27. GuruFocus rates FRA:64Z with a GF Score™ of 44/100 and a GF Value™ of €18.50 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 704 Biotechnology companies, Keymed Biosciences ranks better than 55.26% on this metric.
The historical rank and industry rank for Keymed Biosciences's Days Payable or its related term are showing as below:
FRA:64Z'
s Days Payable Range Over the Past 10 Years
Min: 64.65 Med: 221.27 Max: 1268.27
Current: 141.43
During the past 7 years, Keymed Biosciences's highest Days Payable was 1268.27. The lowest was 64.65. And the median was 221.27.
FRA:64Z's Days Payable is ranked better than 55.26% of 704
companies
in the Biotechnology industry
Industry Median: 112.83
vs FRA:64Z: 141.43
Keymed Biosciences's Days Payable
declined
from Dec. 2024 (596.91) to Dec. 2025 (128.95).
It may suggest that Keymed Biosciencesaccelerated paying its suppliers.
The historical data trend for Keymed Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Keymed Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Keymed Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a Days Payable of 128.95 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Keymed Biosciences and its competitors. This is 42% below median its historical median of 221.27. Over the past decade, Keymed Biosciences' Days Payable has ranged from 64.65 to 1,268.27. According to the industry distribution chart, Keymed Biosciences ranks #315 out of 704 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Keymed Biosciences' Days Payable too high?
Keymed Biosciences' current Days Payable of 128.95 is 42% below median its 10-year median of 221.27. Over the past 10 years, this metric has ranged from a low of 64.65 to a high of 1,268.27. The Biotechnology industry median Days Payable is 112.83. Keymed Biosciences' value of 128.95 is 14.3% above this industry median. Based on the distribution chart, Keymed Biosciences ranks #315 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #315 out of 704 companies for Days Payable. This puts Keymed Biosciences in the upper half of its industry. The industry median Days Payable is 112.83. Keymed Biosciences' value of 128.95 is 14.3% above this benchmark. Historically, Keymed Biosciences' own Days Payable has ranged from 64.65 to 1,268.27 over the past decade. While the company's 10-year median is 221.27 vs. the industry median of 112.83, Keymed Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keymed Biosciences's current Days Payable of 128.95 is 14.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Keymed Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keymed Biosciences's current Days Payable is 128.95, which is 42% below median its own 10-year median of 221.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.50, compared to a current price of €8.45 — trading 54.3% below its estimated fair value. The current Days Payable is 128.95, which is 42% below median its 10-year median of 221.27 and 14.3% above the Biotechnology industry median of 112.83. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Days Payable is 128.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for FRA:64Z:
Days Payable: 128.95 (42% below median its 10-year median of 221.27)
GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
Industry Position: 14.3% above the Biotechnology median (#315 of 704)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score
Get the complete analysis for FRA:64Z
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
